MOUNTAIN VIEW, Calif., Dec. 19 /PRNewswire/ -- Perlegen Sciences, Inc., a privately-held genetics company, announced today a research collaboration with Bristol-Myers Squibb Company (NYSE: BMY - News) to identify markers for patient response to medications in the company's portfolio. The companies will scan the entire genome of hundreds of clinical trial participants. Perlegen will use high-resolution whole genome association technologies and a portfolio of over 1.5 million Perlegen-identified single nucleotide polymorphisms (SNPs) in the study. Bristol-Myers Squibb will provide Perlegen with undisclosed research funding, milestone payments, and royalties. Perlegen will also obtain certain rights to diagnostics and other intellectual property based on the research results.
"We look forward to employing Perlegen's pharmacogenomics technologies within clinical development," said Nicholas C. Dracopoli, Ph.D., Vice President, Clinical Discovery Technologies at Bristol-Myers Squibb Pharmaceutical Research Institute. "We expect this whole genome association study with Perlegen to identify genetic markers that can be used clinically to help predict a patient's response to novel therapeutics."
"At Perlegen, we seek to apply our high-resolution whole genome analysis technologies to improve the health and well-being of patients," said Brad Margus, CEO of Perlegen. "We are extremely pleased to collaborate with Bristol-Myers Squibb in a study that has the potential for rapid application in the treatment of diseases suffered by millions of people worldwide."... |
